The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Spatial Regulation of RhoA Activity during Pancreatic Cancer Cell Invasion Driven by Mutant p53
Open accessAbstract
The ability to observe changes in molecular behavior during cancer cell invasion in vivo remains a major challenge to our understanding of the metastatic process. Here, we demonstrate for the first time, an analysis of RhoA activity at a subcellular level using FLIM-FRET (fluorescence lifetime imaging microscopy-fluorescence resonance energy transfer) imaging in a live animal model of pancreatic cancer. In invasive mouse pancreatic ductal adenocarcinoma (PDAC) cells driven by mutant p53 (p53R172H), we observed a discrete fraction of high RhoA activity at both the leading edge and rear of cells in vivo which was absent in two-dimensional in vitro cultures. Notably, this pool of active RhoA was absent in noninvasive p53fl knockout PDAC cells, correlating with their poor invasive potential in vivo. We used dasatanib, a clinically approved anti-invasive agent that is active in this model, to illustrate the functional importance of spatially regulated RhoA. Dasatanib inhibited the activity of RhoA at the poles of p53R172H cells in vivo and this effect was independent of basal RhoA activity within the cell body. Taken together, quantitative in vivo fluorescence lifetime imaging illustrated that RhoA is not only necessary for invasion, but also that subcellular spatial regulation of RhoA activity, as opposed to its global activity, is likely to govern invasion efficiency in vivo. Our findings reveal the utility of FLIM-FRET in analyzing dynamic biomarkers during drug treatment in living animals, and they also show how discrete intracellular molecular pools might be differentially manipulated by future anti-invasive therapies. Cancer Res; 71(3); 747–57. ©2011 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drug Resistance and the Solid Tumor Microenvironment
Tredan, O., Galmarini, C. M., Patel, K., & Tannock, I. F. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm135 · Cited by 2,116 · cited 1×
“This is likely to be due to critical differences within the solid tumor cell mass, for example due to poor vasculature or limited perfusion and access of the drug to key areas of the tumor (47).”
Gaggioli, C., Hooper, S., Hidalgo-Carcedo, C., Grosse, R., Marshall, J. F., Harrington, K., & Sahai, E. (2007) · Nature Cell Biology · doi:10.1038/ncb1658 · Cited by 1,589 · cited 2×
“We established organotypic cultures of primary human fibroblasts and rat tail fibrillar collagen I (33, 40), which when exposed to an air–liquid interface creates a chemotactic gradient that induces invasion of overlayed cancer cells”
Aguirre, A. J., Bardeesy, N., Sinha, M., Lopez, L., Tuveson, D. A., Horner, J., Redston, M. S., & DePinho, R. A. (2003) · Genes & Development · doi:10.1101/gad.1158703 · Cited by 1,033 · cited 5×
“Initiating KRAS mutations occur in approximately 90% of human PDACs (18-20) while TP53 mutations arise in 50-75% of human pancreatic cancers (21).”
InfluentialDeciphering the transcriptional complex critical for RhoA gene expression and cancer metastasis
Chan, C.-H., Lee, S.-W., Li, C.-F., Wang, J., Yang, W.-L., Wu, C.-Y., Wu, J., Nakayama, K. I., Kang, H.-Y., Huang, H.-Y., et al. (2010) · Nature Cell Biology · doi:10.1038/ncb2047 · Cited by 209
Nalbant, P., Chang, Y.-C., Birkenfeld, J., Chang, Z.-F., & Bokoch, G. M. (2009) · Molecular Biology of the Cell · doi:10.1091/mbc.e09-01-0041 · Cited by 148
Cited by
Datta, R., Heaster, T. M., Sharick, J. T., Gillette, A. A., & Skala, M. C. (2020) · Journal of Biomedical Optics · doi:10.1117/1.jbo.25.7.071203 · Cited by 880
Mutant p53 as a guardian of the cancer cell
Mantovani, F., Collavin, L., & Del Sal, G. (2019) · Cell Death & Differentiation · doi:10.1038/s41418-018-0246-9 · Cited by 775
Tumour-associated mutant p53 drives the Warburg effect
Zhang, C., Liu, J., Liang, Y., Wu, R., Zhao, Y., Hong, X., Lin, M., Yu, H., Liu, L., Levine, A. J., et al. (2013) · Nature Communications · doi:10.1038/ncomms3935 · Cited by 434
The Hippo pathway in cancer: YAP/TAZ and TEAD as therapeutic targets in cancer
Cunningham, R., & Hansen, C. G. (2022) · Clinical Science · doi:10.1042/cs20201474 · Cited by 326
Miller, B. W., Morton, J. P., Pinese, M., Saturno, G., Jamieson, N. B., McGhee, E., Timpson, P., Leach, J., McGarry, L., Shanks, E., et al. (2015) · EMBO Molecular Medicine · doi:10.15252/emmm.201404827 · Cited by 286
Self-citation
Metadata
- Authors
- Timpson, P., McGhee, E. J., Morton, J. P., von Kriegsheim, A., Schwarz, J. P., Karim, S. A., Doyle, B., Quinn, J. A., Carragher, N. O., Edward, M., Olson, M. F., Frame, M. C., Brunton, V. G., Sansom, O. J., & Anderson, K. I.
- Venue
- Cancer Research
- Published
- 2011-02-01
- Volume
- 71
- Issue
- 3
- Pages
- 747-757
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2056850877
- Cited by
- 162
- References
- 5
- FWCI
- 6.94
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Spatial Regulation of RhoA Activity during Pancreatic Cancer Cell Invasion Driven by Mutant p53. https://app.cochat.ai/papers/10.1158/0008-5472.can-10-2267
- The paper
- Timpson, P., McGhee, E. J., Morton, J. P., von Kriegsheim, A., Schwarz, J. P., Karim, S. A., Doyle, B., Quinn, J. A., Carragher, N. O., Edward, M., Olson, M. F., Frame, M. C., Brunton, V. G., Sansom, O. J., & Anderson, K. I. (2011). Spatial Regulation of RhoA Activity during Pancreatic Cancer Cell Invasion Driven by Mutant p53. Cancer Research. https://doi.org/10.1158/0008-5472.can-10-2267
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.